Dr. Padda Explains the Current Role of Immunotherapy in EGFR-Mutant Lung Cancer
Sukhmani Padda, MD, discusses the role of immunotherapy in patients with <em>EGFR</em>-positive non–small cell lung cancer.
Sukhmani Padda, MD, an assistant professor of medicine at Stanford Cancer Institute, discusses the role of immunotherapy in patients withEGFR-positive nonsmall cell lung cancer (NSCLC).
Immunotherapy has not been the biggest hit yet for this patient population, says Padda. However, it can play a role in a more selective patient population.
Immunotherapy should only be considered for these patients withEGFR-mutant NSCLC after all targeted therapies have been tried, as well as a platinum doublet chemotherapy. However, even in patients with high PD-L1 expression, the response rates with immunotherapy have not been that high.
